DFFN - Diffusion Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.2500
-0.0300 (-1.32%)
At close: 3:47PM EST
Stock chart is not supported by your current browser
Previous Close2.2800
Open2.3200
Bid2.25 x 1000
Ask2.40 x 800
Day's Range2.2200 - 2.3300
52 Week Range1.8300 - 11.2500
Volume26,140
Avg. Volume370,183
Market Cap7.597M
Beta (3Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-12.36
Earnings DateMar 27, 2019 - Apr 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.75
Trade prices are not sourced from all markets
  • GlobeNewswire17 days ago

    Diffusion Pharmaceuticals Chief Executive Officer David Kalergis to Present at 37th Annual J.P. Morgan Healthcare Conference

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that Chief Executive Officer David Kalergis will join investors, executives, civic leaders, and scientists to present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 7:00pm EST/4:00pm PST. The Conference will be held on January 7-10, 2019 at the Westin St. Francis Hotel in San Francisco, California.

  • GlobeNewswire18 days ago

    Diffusion Pharmaceuticals Executes Successful NASDAQ Compliance Plan: Company Will Remain Listed on NASDAQ Stock Market

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, today announced it received notice from NASDAQ staff that the Company has regained compliance with Listing Rule 5550(a)(2) and will remain listed on the NASDAQ stock market. The news came as a result of the closing bid price of Diffusion’s stock remaining above $1.00 per share between December 14 and December 28, 2018. This latest news follows a number of exciting recent developments, including FDA approval of a Phase 2 on-ambulance clinical trial for the treatment of stroke using the Company’s lead drug, Trans Sodium Crocetinate (TSC) and the U.S. Patent Office awarding the Company a patent for the use of TSC in conjunction with Tissue Plasminogen Activator (tPA), which remains the only FDA-approved therapeutic stroke treatment.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Evofem Biosciences had a day of gains on Monday after announcing positive results on its hormone free birth control gel. Shares of Diffusion Pharmaceuticals were in the red despite announcing that the company was awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke.

  • ACCESSWIRElast month

    4 Stocks Providing Investor Opportunity Right Now

    On Monday 12/17/2018, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Diffusion Pharmaceuticals Inc. (DFFN), Evofem Biosciences, Inc. (EVFM) and Synergy Pharmaceuticals Inc. (SGYP) are presenting investors with upside opportunity ahead of Christmas and the 2019 New Year. Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) a company you may have not heard of yet, has seen a strong month of bullish trading and shares of the company have climbed by as much as 31% over the last 30 days. The Company has been focusing on a growth strategy with key announcements which continue to build new interest.

  • GlobeNewswirelast month

    U.S. Patent Office Awards Diffusion Exclusive Rights for Use of TSC in Conjunction with Only FDA-Approved Stroke Therapeutic

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that it has been awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke. Currently, tPA – a thrombolytic used to break down blood clots in patients suffering from ischemic stroke – is the only FDA-approved therapeutic stroke treatment.

  • GlobeNewswirelast month

    Diffusion Pharmaceuticals Announces 1-for-15 Reverse Stock Split As Part Of NASDAQ Compliance Plan

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-15, effective for trading purposes prior to the opening of the market on December 14, 2018. The Company’s ticker symbol, DFFN, will remain unchanged. The new CUSIP number for Diffusion’s post-reverse split common stock will be 253748 305.

  • Zacks Small Cap Researchlast month

    DFFN: Phase 2 Clinical Trial of TSC in Acute Stroke to Commence in 2019…

    In early 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced the acceptance of an abstract titled “PreHospital Acute Stroke Therapy with Trans Sodium Crocetinate (PHAST-TSC)” to be presented at the International Stroke Conference. The abstract discussed the design and rationale for a planned Phase 2 study of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation, in patients with acute ischemic (from a clot) or hemorrhagic (from a bleed) stroke. The Pre-Hospital Ambulance Stroke Trial – TSC (PHAST-T) will be a randomized, double blind, placebo controlled trial with an anticipated enrollment of 160 ambulance-transported patients treated within two hours of the onset of a suspected stroke.

  • GlobeNewswire2 months ago

    Diffusion Pharmaceuticals Chief Scientific Officer Dr. John L. Gainer to Present at 2018 Annual Meeting of the Society for NeuroOncology

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that Chief Scientific Officer Dr. John L. Gainer will join leading clinicians and researchers from around the world in presenting a poster at the 2018 Annual Meeting of the Society for NeuroOncology (SNO) on Saturday, November 17, 2018 from 5:00-7:00pm EST. SNO’s 23rd Annual Scientific Meeting and Education Day will be held from Thursday, November 15, 8:00am through Sunday, November 18, 1:00pm at the Marriott Hotel, New Orleans, Louisiana.

  • GlobeNewswire2 months ago

    Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    Highlights Include FDA Approval of Phase 2 On-Ambulance Clinical Trial for Treatment of Stroke and Appointment of New Chief Financial Officer CHARLOTTESVILLE, Va., Nov. 14,.

  • Zacks Small Cap Research5 months ago

    DFFN: Enrollment Continues in Phase 3 Trial of TSC in GBM

    Early in 2018, Diffusion (DFFN) announced that the first patient has been dosed in the Phase 3 INvestigating Tsc Against Cancerous Tumors (INTACT) clinical trial. The trial is anticipated to screen 300 patients with inoperable glioblastoma multiforme (GBM) and enroll 264 such that results from 236 patients will be available for analysis. Patients will be randomized 1:1 to receive TSC along with standard of care radiation and chemotherapy (temozolimide) or standard of care alone.

  • Zacks Small Cap Research8 months ago

    DFFN: Preparing for Phase 2 Clinical Trial of TSC in Acute Stroke

    In early 2018, Diffusion (DFFN) announced the acceptance of an abstract titled “PreHospital Acute Stroke Therapy with Trans Sodium Crocetinate (PHAST-TSC)” to be presented at the International Stroke Conference. The abstract discussed the design and rationale for a planned Phase 2 study of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation, in patients with acute ischemic (from a clot) or hemorrhagic (from a bleed) stroke. The Pre-Hospital Ambulance Stroke Trial – TSC (PHAST-T) will be a randomized, double blind, placebo controlled trial with an anticipated enrollment of 160 ambulance-transported patients treated within two hours of the onset of a suspected stroke.

  • Zacks Small Cap Research9 months ago

    DFFN: Enrollment in Phase 3 GBM Trial Continuing

    On April 3, 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced financial results for 2017 and provided a business update. The primary outcome of the study is overall survival at two years between the two groups.

  • ACCESSWIRE10 months ago

    Diffusion Pharmaceuticals to Present at The MicroCap Conference

    NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (''Diffusion'' or ''the Company''), a clinical-stage biotechnology company focused on extending the life expectancy ...